The chemical class identified as DNA Pol ε A Activators encompasses a spectrum of compounds that, while not known to directly activate DNA Polymerase epsilon A (DNA Pol ε A), have the potential to influence its functional dynamics through the modulation of associated cellular pathways and processes. DNA Pol ε A, a key enzyme in DNA replication and repair, plays a crucial role in maintaining the fidelity and integrity of genetic information during cell division. The compounds within this class, such as aphidicolin, gemcitabine, and 5-fluorouracil, are recognized for their interactions with DNA synthesis and replication processes. Their mechanisms of action, which either involve inhibition of DNA synthesis or incorporation into DNA, can create an environment where the activity of DNA replication machinery, including DNA Pol ε A, becomes crucial. For instance, aphidicolin's role as a DNA synthesis inhibitor might necessitate a compensatory response in DNA replication processes, potentially influencing the activity of DNA Pol ε A. Similarly, gemcitabine, a nucleoside analog, when incorporated into DNA, may indirectly necessitate enhanced DNA repair mechanisms, thus potentially impacting DNA Pol ε A function.
Furthermore, this class includes compounds such as hydroxyurea, cisplatin, and etoposide, which affect various aspects of DNA replication and repair. Hydroxyurea's inhibition of ribonucleotide reductase impacts deoxyribonucleotide levels, potentially affecting DNA replication processes involving DNA Pol ε A. Cisplatin and carboplatin, known for forming DNA adducts, might indirectly impact DNA repair pathways, potentially influencing the role of DNA Pol ε A in these processes. Etoposide and camptothecin, as topoisomerase inhibitors, might also indirectly affect DNA replication processes, necessitating an enhanced role for DNA Pol ε A. Other agents in this class, such as the anthracycline antibiotic doxorubicin and the PARP inhibitor olaparib, demonstrate the potential for altering DNA repair mechanisms, which might indirectly impact DNA Pol ε A activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Can modulate IGF signaling, potentially influencing PAPP-A activity in metabolic pathways. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $146.00 $265.00 | 1 | |
An IGF-1R inhibitor, could impact PAPP-A activity by modulating IGF signaling pathways. | ||||||
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $138.00 $203.00 $895.00 | 63 | |
An IGF-1R inhibitor, might affect pathways involving PAPP-A. | ||||||
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
Another IGF-1R inhibitor, could potentially influence PAPP-A activity by affecting IGF signaling. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Known for its effects on insulin/IGF signaling, might impact PAPP-A indirectly. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
A lipoxygenase inhibitor, might impact cellular processes related to PAPP-A. | ||||||
Bexarotene | 153559-49-0 | sc-217753 sc-217753A | 10 mg 100 mg | $55.00 $250.00 | 6 | |
A retinoid X receptor agonist, could potentially influence PAPP-A through pathways involving cell growth and differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, potentially impacting signaling pathways related to PAPP-A. | ||||||